Effect of prophylactic HEPATOGARD treatment on the incidence of hepatotoxicity in patients receiving anti – tuberculosis drugs

Article published in The Bombay Hospital Journal (Vol.34, No. 4, 1992, PP. 35-40)


In a double blind placebo controlled trial, 205 patients suffering from pulmonary tuberculosis receiving isoniazid, rifampicin, ethambutol and streptomycin were studied for effect of simultaneous administration of Hepatogard 3 Tablets 3 times a day during 1st two months of intensive therapy on the incidence of hepatotoxicity and clinical morbidity. No patients in drug treated group developed jaundice whereas one patient from controls developed jaundice. Overall incidence of abnormalities in liver function tests was low, but more number of patients in controls tended to record abnormal values than the drug treated patients.

Rapid restoration of appetite and feeling of well being was observed in drug treated group. Significant differences in favor of drug treatment were observed in the pattern of weight gain at the end of 8 weeks of treatment. No serious adverse effects attributable to Hepatogard treatment were observed. 

Clinical trial of HEPATOGARD in acute viral hepatitis

Article published in The Indian Practitioner (Vol. XLVI, Feb 1993, No. 2, PP. 141-151)


In a double blind placebo controlled trial, Hepatogard, a herbal formulation was evaluated in 62 patients of acute viral hepatitis. The clinical parameters viz., anorexia, nausea-vomiting, malaise, icterus, liver tenderness and hepatomegaly decreased markedly on the drug as compared to the placebo. The total serum bilirubin was elevated in the placebo group at the end of four days while during the same period, total serum bilirubin values in Hepatogard group dropped.

The difference between the placebo and the drug was significant (P < 0.005). The decline continued to be significant for next three weeks. Similar significant decline in serum transaminase values was observed. No serious adverse effects were observed.

Enquire Now